[Featured Stock] Samsung Biologics Rises Over 8% on 400 Billion KRW Contract for Contract Manufacturing
[Asia Economy Reporter Oh Ju-yeon] On the 10th, Samsung Biologics' stock price surged by over 8%, showing strong performance.
On the same day, Samsung Biologics announced that it signed a letter of intent for a contract worth 441.8 billion KRW for the contract manufacturing of biopharmaceuticals with a U.S.-based pharmaceutical company.
Following this news, Samsung Biologics' stock price quickly surpassed the 500,000 KRW mark.
As of 9:58 AM, Samsung Biologics' stock price was trading at 517,000 KRW, up 8.05% compared to the previous trading day.
Hot Picks Today
If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- "Profit Distribution Without Shareholders’ Approval Is Invalid"... Samsung Electronics Shareholder Group Announces Lawsuit Over 'Provisional Agreement'
- Room Prices Soar from 60,000 to 760,000 Won and Sudden Cancellations: "We Won't Even Buy Water in Busan" — BTS Fans Outraged
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
After falling to the 360,000 KRW range on the 19th of last month, Samsung Biologics has since hovered around the 400,000 KRW range.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing 90 Degrees These Days Actually Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
